No gainer or loser data available.

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Interviews

Rivco Australia is the only ASX-listed company giving investors direct access to Australian water entitlements, with 61 gigalitres across the southern Murray-Darling Basin. Since bringing management in-house last November, the company has lifted the share of its portfolio leased to farmers from about 50 per cent to 80 per cent. Ahead of presenting at the TIP Conference, Rivco Executive Manager, Corporate Lachlan Campbell joins The Stock Network's Lel Smits to discuss the shrinking supply of water in the Murray and the road ahead for the company. 1. Positioning Rivco's water portfolio where Murray supply is tightest Rivco holds most of its water in the Lower Murray, below the Barmah Narrows, as government buybacks remove water from farming. Why is supply tightest there, and how does that support Rivco's lease income? 2. Signing Australia's largest irrigators as long-term tenants Rivco aims to have 10 of Australia's largest irrigators leasing its water. What are the key steps to get there in the year ahead? 3. Water challenges in California The challenges in California with respect to water have been well documented - what are your views on the situation? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Rivco Australia (ASX:RIV): Leasing water to irrigators as Murray supply tightens
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS4yQjdDRUQyQ0M0MEZCQkEx

Rivco Australia (ASX:RIV): Leasing water to irrigators as Murray supply tightens

Solvar, the specialist lender behind Money3, Automotive Financial Services (AFS) and Bennji, has entered FY27 with an Australian loan book above $1 billion for the first time. The group has more than $400 million of funding headroom to support growth across consumer and commercial lending. Ahead of presenting at the TIP Conference, Solvar CEO and Managing Director Scott Baldwin joins The Stock Network’s Lel Smits to discuss loan book momentum, credit quality and Bennji’s commercial lending opportunity. 1. Building on loan book growth in FY27 Solvar’s Australian loan book grew 6.4% in the first quarter, with growth across all operating segments. What is driving this momentum, and why does reaching a $1 billion loan book create an important earnings opportunity for FY27 and FY28? 2. Managing credit quality across Solvar’s loan book Bad debts finished FY26 at 4.4% of gross receivables, at the upper end of the target range. What are you seeing in customer behaviour amid cost-of-living pressures, and how are you managing credit quality and impairment provisioning? 3. Bennji becoming a second growth engine Commercial lending has continued to build momentum, with the loan book reaching about $150 million at the end of the first quarter. How are you leveraging Money3’s existing broker and customer channels to grow Bennji, and when could it become a meaningful contributor? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Solvar (ASX:SVR): Loan book growth, funding advantage and FY27 opportunity
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS4xM0YyQUYxQTg5OTgyQ0Y5

Solvar (ASX:SVR): Loan book growth, funding advantage and FY27 opportunity

EBR Systems continues its US rollout of the WiSE® CRT System, the world's only wireless cardiac pacing device for heart failure. Since last speaking with The Stock Network in June, the number of physicians trained to implant WiSE® has reached one hundred, and EBR has now signed more than fifty hospital purchasing contracts. EBR Systems Chief Corporate Development Officer Andrew Shute joins The Stock Network's Lel Smits to discuss Medicare payments, hospital uptake and the move to in-house manufacturing. Questions 1. Gaining higher Medicare hospital payments for WiSE® procedures This month Medicare moved eligible WiSE® procedures into the same higher-paying groups as leadless pacemakers. What are the implications for the WiSE® rollout? 2. Deepening WiSE® utilisation inside activated hospitals EBR's field team is now focused on hospitals already performing WiSE®, with John McCutcheon leading the commercial organisation directly. What helps a hospital move from occasional WiSE® cases to a regular implant schedule? 3. Preparing Santa Clara WiSE® manufacturing for FDA approval The FDA has completed its inspection of EBR's new Santa Clara facility, which has also gained international quality certification. What remains before the site is approved, and what other milestones are ahead into next year? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
EBR Systems (ASX:EBR): Securing higher Medicare payments for WiSE® & readying in-house manufacturing
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS4xNkVFQkQwQzlCOTczN0FG

EBR Systems (ASX:EBR): Securing higher Medicare payments for WiSE® & readying in-house manufacturing

Imagion Biosystems is testing MagSense®, a non-radioactive imaging agent designed to help MRI scans detect cancer earlier and more precisely, starting with HER2-positive breast cancer. Since last speaking with The Stock Network in September, the company has secured central ethics approval for its US clinical trial, selected five clinical sites and restarted nanoparticle manufacturing. Imagion Biosystems Chair Bob Proulx joins The Stock Network's Lel Smits to discuss how MagSense® compares with today's imaging, what the trial needs to show and the wider pipeline. 1. Challenging PET scans with non-radioactive MagSense® MRI Imagion positions MagSense® as an alternative to radioactive PET imaging that works on existing MRI scanners. Where does it sit against PET and standard contrast MRI for a breast cancer patient? 2. Testing MagSense® against lymph node biopsy Early clinical data suggested MagSense® could help tell cancerous lymph nodes from healthy ones. What will the US trial need to show for surgeons to rely on it over a biopsy? 3. Extending MagSense® to prostate and ovarian cancer Changing the targeting molecule lets MagSense® look for other cancers. How are you prioritising prostate and ovarian cancer, and what milestones are ahead for those programs? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Imagion Biosystems (ASX:IBX): Opening US trial sites for MagSense® breast cancer imaging
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS4xQzNEQjU3NzFFNzQ1M0Q0

Imagion Biosystems (ASX:IBX): Opening US trial sites for MagSense® breast cancer imaging

Christopher Marr is a Partner in the Melbourne office of Steinepreis Paganin, a corporate law firm advising ASX-listed and unlisted companies on equity capital markets, mergers and acquisitions, corporate transactions and financial services. Ahead of Stocks on Location, Chris joins The Stock Network's Lel Smits to discuss what boards should know before raising capital, how takeovers really play out and where legal structuring protects shareholder value. 1. Capital raisings and protecting shareholder value With small caps relying on placements, rights issues and SPPs to fund growth, what should shareholders consider when companies need to raise, and what are the common mistakes you see from companies? 2 M&A, takeovers and getting deals done You have acted on public and private M&A and Takeovers Panel matters. What separates deals that complete from those that fall over, and how should shareholders read a takeover approach? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Steinepreis Paganin: Capital raisings, M&A and protecting shareholder value on the ASX
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS4xMUQ5ODk0Q0I0MjZBQjhG

Steinepreis Paganin: Capital raisings, M&A and protecting shareholder value on the ASX

Robotic technology company FBR (ASX:FBR) is advancing its Mantis® high-deposition welding robot, which is now commissioned and undergoing trials ahead of Factory Acceptance Testing. With its first unit pre-sold to the US and a new North American distribution partnership in place, Mantis is moving closer to commercial deployment and a potentially significant new market opportunity. Ahead of appearing at Stocks on Location, FBR CEO Mark Pivac joins The Stock Network’s Lel Smits to discuss Mantis, the North American opportunity and the next phase of FBR’s robotics growth. 1. Mantis moves towards commercialisation Mantis is now undergoing welding trials ahead of Factory Acceptance Testing, with the first unit already pre-sold to the US. What are the key milestones from here, and how close is Mantis to commercial deployment? 2. Unlocking the North American market FBR has appointed a North American distributor for Mantis, opening a pathway into industrial fabrication and shipbuilding. How significant could this market be for FBR, and what is the strategy for turning this opportunity into broader commercial adoption? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
FBR (ASX:FBR): Mantis moves towards commercialisation as global robotics opportunity expands
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS45NTBGQjA2RDUzMTJFM0VF

FBR (ASX:FBR): Mantis moves towards commercialisation as global robotics opportunity expands

Starpharma (ASX:SPL, US OTC:SPHRY) has seen its share price rise more than 100% this year as it advances its dendrimer drug-delivery platform, partnerships and clinical programs. With major partnerships including Genentech and Radiopharm Theranostics, alongside its DEP® HER2-Lu program progressing towards the clinic, Starpharma is building momentum across its pipeline and commercial opportunities. Ahead of appearing at Stocks on Location, Starpharma CEO Cheryl Maley joins The Stock Network’s Lel Smits to discuss what is driving the company’s momentum and the catalysts ahead. 1. Factors behind Starpharma's 100%+ share price rise Starpharma’s share price has risen more than 100% this year. What are the key factors driving this momentum, and what has changed for the company over the past 12 months? 2. Big pharma validation and the next catalyst With partnerships including Genentech and Radiopharm and DEP® HER2-Lu moving towards the clinic, can you talk us through your strategy for securing continued validation and growing partnerships? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Starpharma (ASX:SPL, US OTC:SPHRY): Building momentum across drug delivery from platform to clinic
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS4yNDgyN0RCRjQ1QTUxRUMy

Starpharma (ASX:SPL, US OTC:SPHRY): Building momentum across drug delivery from platform to clinic

James Leslie-Watt is Managing Partner of Corson Fiske Australia & New Zealand, a multidisciplinary firm specialising in business advisory, accounting, restructuring, intellectual property and commercial legal services. Ahead of Stocks on Location, James joins The Stock Network’s Lel Smits to discuss how Australian business owners and directors can navigate financial pressure, protect intellectual property and position their businesses for long-term growth. 1. Scaling in a challenging economy With rising costs, tighter capital and growing regulatory complexity, what separates businesses that scale successfully from those that struggl, and what structural decisions should directors make before pursuing growth? 2. Acting early on financial pressure What early warning signs of financial stress should directors never ignore, and how does seeking advice sooner improve outcomes for businesses and stakeholders? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Corson Fiske: Strategic advice on business growth, restructuring & value protection
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS5BNEY4RDc0MzMyNDAyQjAx

Corson Fiske: Strategic advice on business growth, restructuring & value protection

Peter Angelini is Managing Director of Stannards, a multidisciplinary accounting and advisory firm supporting businesses through audit, tax, external CFO services, R&D, corporate advisory and valuations. Ahead of Stocks on Location, Peter joins The Stock Network’s Lel Smits to discuss tax-efficient business structures, successful succession planning and the lessons behind Stannards’ rapid expansion - including approximately 50% revenue growth and an increase in its team from 75 to 120 people over the past two years. 1. Tax planning and protecting shareholder value With significant tax changes being proposed and enacted, why should corporate and family groups consider their tax structures well before a growth, succession or exit event? What should shareholders be doing now to ensure their personal structures remain tax-efficient? 2. Succession and scaling successfully You succeeded your father as Managing Director after he led Stannards for approximately 30 years. What made that transition successful, and how have those lessons influenced Stannards’ growth since partnering with Pemba Capital in 2024? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Stannards: Tax planning, succession and scaling a business successfully
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS5EQjk2Mzc4OTUzQTQ4NDlB

Stannards: Tax planning, succession and scaling a business successfully

View More

Get the latest ASX stock market news delivered to your inbox

By proceeding, you can confirm you understand that we handle personal informational in accordance with our Privacy Policy